Immune system alterations in patients with inflammatory bowel disease during remission

Medicina

Volumn 44, Issue 1, 2008, Pages 27-33

  Šventoraityte, Jurgita ^a   Žvirbliene, Aida ^a   Kiudelis, Gediminas ^a   Žalinkevičius, Rimantas ^a   Žvirbliene, Aurelija ^a   Praškevičius, Antanas ^a   Kupčinskas, Limas ^a   Tamošiunas, Vytas ^b  

^a KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

^b VYTAUTAS MAGNUS UNIVERSITY   (Lithuania)

Author keywords

Crohn's disease, ulcerative colitis; Inflammatory bowel disease; Th1 and Th2 cytokines

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; CROHN DISEASE; ENTERITIS; EVALUATION; FEMALE; HOMEOSTASIS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; REMISSION; STATISTICAL ANALYSIS; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS;

ADULT; AGED; CELLS, CULTURED; COLITIS, ULCERATIVE; CROHN DISEASE; CYTOKINES; DATA INTERPRETATION, STATISTICAL; FEMALE; HOMEOSTASIS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON TYPE II; INTERLEUKIN-10; MALE; MIDDLE AGED; REMISSION INDUCTION; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40949151599     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina44010005     Document Type: Article

References (27)

1. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007;102(9):2058-69.
2. Žvirblienee A, Kiudelis G, Kupčinskas L. Retrospective analysis of case histories of patients with ulcerative colitis and Crohn's disease. Medicina (Kaunas) 2003;39(8):745-50.
3. Žvirbliene A, Kiudelis G, Žalinkevičius R, Kupčinskas L. Dietary characteristics of patients with inflammatory bowel diseases. Medicina (Kaunas) 2006;42(11):895-9.
4. Nagler-Anderson C. Man the barrier! Strategic defences in the intestinal mucosa. Nat Rev Immunol 2001;1(1):59-67.
5. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol 2002;2(1):37-45.
6. Dignass AU, Baumgart DC, Sturm A. Review article: The aetiopathogenesis of inflammatory bowel disease - immunology and repair mechanisms. Aliment Pharmacol Ther 2004;20(4):9-17.
7. Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 2004;50(2):81-92.
8. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495-549.
9. Elson CO, Conf. Y, McCracken VJ, Dimmitt RA, Lorenz RG, Weaver CT. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev 2005;206: 260-76.
10. Martinez-Montiel MP, Munoz-Yague MT. Biologic therapies for chronic inflammatory bowel disease. Rev Esp Enferm Dig 2006;98(4):265-91.
11. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3(7): 521-33.
12. Podolsky DK. Inflammatory bowel disease (1). N Engl J Med 1991;325(13):928-37.
13. Gomes P, Du Boulay C, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986;27:92-5.
14. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
15. Bisping G, Lügering N, Lütke-Brintrup S, Pauels HG, Schürmann G, Domschke W, et al. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells. Clin Exp Immunol 2001;123:15-22.
16. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991;32:913-7.
17. Raddatz D, Bockemühl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: Relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005;17(5):547-57.
18. Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Araake H, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001;47(70):1297-301.
19. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992;33(6):773-8.
20. Wilde DB, Prystowsky MB, Ely JM, Vogel SN, Dialynas DP, Fitch FW. Antigen-reactive cloned helper T cells. II. Exposure of murine cloned helper T cells to IL 2-containing supernatant induces unresponsiveness to antigenic restimulation and inhibits lymphokine production after antigenic stimulation. J Immunol 1984;133(4):636-41.
21. Kaiser GC, Yan F, Polk D. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999;116(3):602-9.
22. Gomez-Munoz A, O'Brien L, Salh B, Steinbrecher UP. 5-Aminosalicylate stimulates phospholipase D activity in macrophages. Biochim Biophys Acta 2001;1533(2):110-8.
23. Mitsuyama K, Tomiyasu N, Takaki K, Masuda J, Yamasaki H, Kuwaki K, et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediators Inflamm 2006;2006(6): 1-7.
24. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1cells. J Immunol 1991;146(10):3444-51.
25. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147(11):3815-22.
26. Kucharzik T, Lügering N, Weigelt H, Adolf M, Domschke W, Stoll R. Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10. Clin Exp Immunol 1996;104(3):483-90.
27. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006;211(6-8):609-18.